Parkinson’s is caused by the insufficient number of neurotransmitters, due to which the patient’s body movements and control are affected. Although drugs are available to lessen these issues, their efficacy decreases over time. Therefore, Aspen Neuroscience is working on a cell therapy through which Parkinson’s can be treated. Aspen’s approach differs from Bayer’s as the latter intends to employ stem cells of a healthy donor, while the former will utilize the patient’s own stem cells to replace neurons. Now Aspen has received $147m funding which will be employed to test this therapy for the first time on humans. This experiment will also prove whether Aspen’s treatment has an edge over Bayer’s.
Read More from MedCityNews
